---
figid: PMC9014075__bmjopen-2021-060478f01
pmcid: PMC9014075
image_filename: bmjopen-2021-060478f01.jpg
figure_link: /pmc/articles/PMC9014075/figure/F1/
number: Figure 1
figure_title: ''
caption: Trial schema, schema showing the pathway for patients recruited into the
  phase I trial of 89Zirconium-labelled girentuximab (89Zr-TLX250) positron emitting
  tomography (PET) in 89Zirconium-labelled girentuximab PET in Urothelial Cancer Patients
  (ZiPUP). *Vital signs, standard laboratory (full blood count, renal function, basic
  electrolytes and liver function test), 12-lead ECG and concomitant medication recording
  and adverse event recording (NCI-CTCAE V.5.0). NCI-CTCAE V.5.0, National Cancer
  Institute-Common Terminology Criteria for Adverse Effects version V.5.0
article_title: '89Zirconium-labelled girentuximab (89Zr-TLX250) PET in Urothelial
  Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality
  for urothelial carcinoma.'
citation: Mohammed Al-Zubaidi, et al. BMJ Open. 2022;12(4):e060478.
year: '2022'

doi: 10.1136/bmjopen-2021-060478
journal_title: BMJ Open
journal_nlm_ta: BMJ Open
publisher_name: BMJ Publishing Group

keywords:
- Urological tumours
- Nuclear radiology
- NUCLEAR MEDICINE

---
